[Abstract]

Antibody-Drug Conjugates (ADCs) have emerged as one of the fastest growing pharmaceutical class of drugs designed to harness the specificity of antibodies with the potency of small molecule therapeutics. Currently, ten ADCs have been approved for therapeutic use, and the clinical success of these ADCs

have sparked clinical development of novel ADCs. Lessons learned during the past decade are now being used in the development of next-generation ADCs. LegoChem Biosciences (LCB) has developed a novel next-generation site-specic ADC platform with novel linker chemistry that improves stability of ADCs in

blood circulation, effectively prevents premature drug release, eciently facilitates the liberation of the drug at the targeted tumor cells and ultimately shows signicant improved therapeutic index. In addition, this presentation highlights LCB’s tumor-selective and potent ADC with superior efficacy and reduced toxicity.